Showing 1251-1260 of 1395 results for "".
- Visiox Pharma Licenses Glaucoma Drug Omlonti from Santenhttps://modernod.com/news/visiox-pharma-licenses-glaucoma-drug-omlonti-from-santen/2481736/Visiox Pharma announced it has entered into a definitive agreement with Santen Pharmaceutical to license glaucoma drug Omlonti (omidenepag isopropyl ophthalmic solution 0.002%). Specific financial terms of the deal were not disclosed. Omlonti was approved by th
- FDA Rejects Aldeyra's NDA for Rare Eye Cancer Drug ADX-2191https://modernod.com/news/fda-rejects-aldeyras-nda-for-rare-eye-cancer-drug-adx-2191/2481684/The FDA issued a Complete Response Letter to Aldeyra Therapeutics for the NDA of ADX-2191 (methotrexate for injection, USP), an investigational drug candidate for the treatment of primary vitreoretinal lymphoma (PVRL). Although no safety or manufacturing issues with ADX-2191 w
- CORE Publishes Resource on Ectatic Corneal Diseaseshttps://modernod.com/news/core-publishes-resource-on-ectatic-corneal-diseases/2481670/As ectatic corneal diseases—such as keratoconus—pose significant challenges to vision and quality of life, the Centre for Ocular Research & Education (CORE) has dedicated Issue 72 of
- International Ophthalmology Panel Calls for Recognizing and Treating Childhood Myopia as a Diseasehttps://modernod.com/news/international-ophthalmology-panel-calls-for-recognizing-and-treating-childhood-myopia-as-a-disease/2481607/Responding to one of the greatest eye health issues in a generation, nine internationally recognized pediatric ophthalmologists have come together to call for greater recognition of childhood myopia as a disease and earlier treatment of children. Their perspectives are now available as a white pa
- Medical Consulting Group and Corcoran Consulting Group Announce Mergerhttps://modernod.com/news/medical-consulting-group-and-corcoran-consulting-group-announce-merger/2481571/Medical Consulting Group (MCG), a provider of consulting services to ophthalmic practices and companies, and Corcoran Consulting Group (CCG), a company specializing in billing, coding, and reimbursement issues for ophthalmology and optometry practices, today announced a definitive merger agreemen
- CDC Provides Update on Pseudomonas Aeruginosa Associated with Artificial Tearshttps://modernod.com/news/cdc-provides-update-on-pseudomonas-aeruginosa-associated-with-artificial-tears/2481382/The Centers for Disease Control and Prevention (CDC) issued a Health Alert Network (HAN) Health Advisory in regards to infections of 55 people in 12 states related to the use of artificial tears. Patients with infections reported more than 10 different brands of artifici
- Harrow Announces Permanent, Product-Specific J-Code for Iheezo for Ocular Surface Anesthesiahttps://modernod.com/news/harrow-announces-permanent-product-specific-j-code-j2403-for-iheezo-for-ocular-surface-anesthesia/2481378/Harrow announced that the Centers for Medicare & Medicaid Services (CMS) has issued a permanent, product-specific J-code for Iheezo (chloroprocaine hydrochloride ophthalmic gel) 3% for ocular surface anesthesia. Under the Healthcare Common Procedure Coding System (HCPCS), the Iheezo J‑co
- Mobius Therapeutics Granted New US Patent for Injected Ophthalmic Mitomycin-Chttps://modernod.com/news/mobius-therapeutics-granted-new-us-patent-for-injected-ophthalmic-mitomycin-c/2481319/Mobius Therapeutics has been issued US Patent #11,540,977, "Injection Apparatus and Method of Use," protecting future applications of Mitosol, Mobius’ flagship product, particularly versus compounded, unapproved copies of Mitosol. “This is an important ad
- Outlook Therapeutics Closes $55 Million Financing; Extends Cash Runway Through Anticipated FDA Approval of ONS-5010https://modernod.com/news/outlook-therapeutics-closes-55-million-financing-extends-cash-runway-through-anticipated-fda-approval-of-ons-5010/2481313/Outlook Therapeutics announced it closed on approximately $25 million registered direct equity offering, and about $30 million net proceeds from issuance of an unsecured convertible promissory note with an initial conversion price of $2. The $50 million net proc
- Santen and UBE Receive FDA Approval for Omlonti for the Reduction of Elevated IOP in Patients with Primary Open-Angle Glaucoma or Ocular Hypertensionhttps://modernod.com/news/santen-and-ube-receive-fda-approval-for-omlonti-for-the-reduction-of-elevated-iop-in-patients-with-primary-open-angle-glaucoma-or-ocular-hypertension/2481115/Santen and UBE announced that the FDA has approved Omlonti (omidenepag isopropyl ophthalmic solution) 0.002% eye drops for the reduction of elevated IOP in patients with primary open-angle glaucoma or ocular hypertension. The approval date was September 22. Omi